Efficacy and Safety of Rituximab Treatment in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitides: Results from a German Registry (GRAID)
| Autor: | Marion Haubitz, Falk Hiepe, Stefan Heitmann, Eva Ostermeier, Julia Holle, Rebecca Fischer-Betz, Svjetlana Lovric, Jörg Henes, Gerd-Rüdiger Burmester, Raoul Bergner, Petra Roll, Thomas Dorner, Martin Aringer, Christof Specker, Andrea Rubbert-Roth, L. Unger, Hans-Peter Tony, Ulf Müller-Ladner, Hendrik Schulze-Koops, Martin Fleck, Ina Kötter |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors Immunology Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Gastroenterology Cohort Studies Antibodies Monoclonal Murine-Derived Rheumatology Refractory Germany Internal medicine medicine Humans Immunology and Allergy Registries Aged Retrospective Studies Anti-neutrophil cytoplasmic antibody Dose-Response Relationship Drug business.industry Middle Aged medicine.disease Surgery Treatment Outcome Tolerability Antirheumatic Agents Female Rituximab Granulomatosis with polyangiitis Vasculitis Microscopic polyangiitis business medicine.drug |
| Zdroj: | The Journal of Rheumatology. 39:2153-2156 |
| ISSN: | 1499-2752 0315-162X |
| DOI: | 10.3899/jrheum.120482 |
| Popis: | Objective.Rituximab (RTX) therapy is a treatment option in patients with refractory antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). We investigated the tolerability and clinical efficacy of RTX in a cohort of patients with refractory AAV.Methods.Clinical and safety data of patients with AAV treated with RTX were retrospectively assessed from the data of a German national registry.Results.In total, 58 patients were included in this analysis (50/58 with granulomatosis with polyangiitis; 8/58 with microscopic polyangiitis who received at least 1 cycle, 17 patients who received 2 cycles, and 3 patients who received 3 cycles of RTX). Response was classified as complete and partial in 22 (40%) and in 29 cases (52.7%), respectively. Four patients (7.3%) were classified as nonresponders.Conclusion.RTX was well tolerated with good clinical efficacy in patients with refractory AAV. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|